ANALYSIS OF INDICATION EXPANSIONS FOR ORPHAN-DESIGNATED, FDA-APPROVED DRUGS LAUNCHED IN THE UNITED STATES BETWEEN 2005 AND 2015

被引：0
|
作者：
Li, J. [1 ]
Lai, R. [1 ]
Asabere, A. [1 ]
Bastian, A. [1 ]
机构：
[1] GfK, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.041
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PR4
引用
收藏
页码：A4 / A4
页数：1
相关论文
共 16 条
  • [1] FDA-Approved Anti-Obesity Drugs in the United States
    Daneschvar, Homayoun L.
    Aronson, Mark D.
    Smetana, Gerald W.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2016, 129 (08): : 879.e1 - 879.e6
  • [2] A decade of oncology drug development: FDA-approved drug trends between 2005 and 2015
    Asabere, Akwasi
    Bastian, Alex
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] COMPARATIVE ANALYSIS OF CLINICAL TRIAL ATTRIBUTES IN PIVOTAL STUDIES FOR ORPHAN VS. NON-ORPHAN ONCOLOGY PRODUCTS FDA-APPROVED BETWEEN 2011 AND 2015
    Ansari, W.
    Infante, K.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A750 - A750
  • [4] Price migration of oncology drugs launched in the United States between 2010 and 2015
    Bastian, Alex
    Li, Jessica
    Asabere, Akwasi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] THE RISE OF ORPHAN DRUGS IN EUROPE VS THE UNITED STATES: COMPARING ORPHAN DRUG DESIGNATIONS BETWEEN THE EMA AND FDA
    Mildred, M.
    Lee, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A677 - A677
  • [6] Investigating the factors influencing the prescription of antidepressants with no FDA approved indication in the United States between 2006 and 2009.
    Marriner, Brandy L.
    Tseng, Tina
    Rich, Wesley
    Hall, Ryan
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E304 - E304
  • [7] MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES: ANALYSIS OF DRUGS APPROVED BY THE FDA FROM 1939 TO 2008
    Oureshi, Z. P.
    Szeinbach, S. L.
    Seoane-Vazquez, E.
    Rodriguez-Mongulo, R.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A81 - A82
  • [8] Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
    Hui-Heng Lin
    Le-Le Zhang
    Ru Yan
    Jin-Jian Lu
    Yuanjia Hu
    [J]. Scientific Reports, 7
  • [9] Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
    Lin, Hui-Heng
    Zhang, Le-Le
    Yan, Ru
    Lu, Jin-Jian
    Hu, Yuanjia
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [10] Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016
    Saravanakumar, Anitha
    Sadighi, Armin
    Ryu, Rachel
    Akhlaghi, Fatemeh
    [J]. CLINICAL PHARMACOKINETICS, 2019, 58 (10) : 1281 - 1294
12